Rani Therapeutics Welcomes Eric Groen as General Counsel

Rani Therapeutics Holdings, a clinical-stage biotherapeutics firm focusing on creating technologies to develop orally delivered biologics, named Eric Groen as the General Counsel.

FREMONT, CA: Eric Groen has been named General Counsel at Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics firm focusing on creating technologies to develop orally delivered biologics. Mr. Groen has over 25 years of experience in managing legal affairs in business and private practice.

Mr. Groen has a track record of working in the biopharmaceutical business as a lawyer. Before joining Rani, Mr. Groen worked at Amgen for approximately 20 years in various domestic and international roles with increasing responsibilities, such as heading legal teams responsible for business development deals, operations and manufacturing, and clinical trials. He was recently the regional general counsel for Amgen's commercial operations in Canada, Latin America, the Middle East, and Africa. Mr. Groen started his legal career at the TroyGould law firm, where he focused on corporate finance, securities compliance, corporate governance, and mergers and acquisitions. Mr. Groen graduated from Harvard Law School with a J.D. and UC Santa Barbara with a B.A. in Political Science.

"Eric is an accomplished executive whose legal expertise and business acumen have enabled him to handle complex legal matters across the breadth of biopharmaceutical operations, from R&D to manufacturing to commercial, with particular expertise in leading biopharmaceutical transactions. We look forward to his contributions as we continue to progress the RaniPill^TM capsule technology and advance our clinical pipeline," said Talat Imran, Ranis Chief Executive Officer. "I am thrilled to welcome Eric to our team as we pursue our goal of making oral biologics a reality so that we may be able to help millions of people suffering from chronic diseases."

Rani Therapeutics is a clinical-stage biotherapeutics firm focusing on developing methods that would allow orally delivered biologics to be developed. The RaniPill capsule is a revolutionary, proprietary, and patented platform technology created by Rani to substitute subcutaneous injection of biologics with oral dosage. By using the RaniPill capsule, Rani has undertaken various preclinical and clinical trials to assess safety, tolerability, and bioavailability.